🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hidradenitis

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% NCT06645821EARLY Phase 11 site📍 Norfolk Virginia Clinical Research, Inc. · Tests: EVO101 Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa NCT07109765n/a1 site📍 Beijing Peking Union Medical College · Tests: Secukinumab Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa NCT07244510Phase 21 site📍 Samsun Sinocelltech Ltd. · Tests: SCT650C Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. NCT06326476EARLY Phase 11 site📍 Birmingham University of Alabama at Birmingham · Tests: Siplizumab A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa NCT06932003Phase 1, Phase 21 site📍 Beijing Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158 Tablets Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa NCT07213973Phase 230 sites📍 Birmingham📍 Phoenix📍 Phoenix Incyte Corporation · Tests: Povorcitinib SAR447971 First-in-human Study NCT07629336Phase 11 site📍 Leiden Sanofi · Tests: SAR447971, Placebo SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa NCT07170917Phase 285 sites📍 Phoenix📍 Scottsdale📍 Northridge Sanofi · Tests: Brivekimig, Placebo Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository NCT04115566n/a1 site📍 San Francisco University of California, San Francisco A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) NCT07766005Phase 234 sites📍 Birmingham📍 Rogers📍 Irvine Spyre Therapeutics, Inc. · Tests: SPY072, Placebo, bimekizumab Radiotherapy for Refractory Hidradenitis Suppurativa NCT07414550NA2 sites📍 Cherry Hill📍 Philadelphia Thomas Jefferson University · Tests: Radiated axilla A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa NCT07136467n/a116 sites📍 Ciudad Autonoma de Buenos Aire📍 Buenos Aires📍 Buenos Aires AbbVie Real-world Secukinumab Outcomes in Canadian HS Patients NCT07282015n/a15 sites📍 Calgary📍 Calgary📍 Winnipeg Novartis Pharmaceuticals Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases NCT06599411n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Sampling, Sampling Myriad™ Augmented Soft Tissue Reconstruction Registry NCT05243966n/a15 sites📍 Phoenix📍 Los Angeles📍 Fort Myers Aroa Biosurgery Limited · Tests: Myriad Matrix™ and Myriad Morcells™ Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa NCT07489573Phase 410 sites📍 Guangzhou📍 Shijiazhuang📍 Chengdu Novartis Pharmaceuticals · Tests: Secukinumab Evolution and Treatments of Chronic Inflammatory Systemic Diseases NCT04191395n/a1 site📍 Besançon Centre Hospitalier Universitaire de Besancon A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab NCT06524635Phase 22 sites📍 Sacramento📍 Ann Arbor AbbVie · Tests: Lutikizumab Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa NCT07828860Phase 111 sites📍 West Lafayette📍 Bowling Green📍 Owensboro Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa NCT07547813Phase 21 site📍 Warsaw Almirall, S.A. · Tests: LAD328, Placebo A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa NCT07225569Phase 286 sites📍 Scottsdale📍 North Hollywood📍 Boynton Beach Sanofi · Tests: SAR445399, Placebo A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients NCT06946641Phase 11 site📍 Beijing Shanghai Qilu Pharmaceutical Research and Development Cente… · Tests: QLS12010, Placebo Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI) NCT06368388n/a1 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Prospective data collection phage therapy, Prospective data collection standard-of-care Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort) NCT04352036n/a13 sites📍 Angers📍 Brest📍 La Roche-sur-Yon Nantes University Hospital · Tests: no interventional study Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa NCT05531747NA1 site📍 Créteil Assistance Publique - Hôpitaux de Paris · Tests: Skin biopsy, Blood sample The Ohio State University Dermatology Biorepository NCT03146676n/a1 site📍 Columbus Ohio State University Clinical and Biological Characteristics of Hidradenitis Suppurativa NCT03967600n/a1 site📍 San Francisco University of California, San Francisco A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS NCT07855276Phase 11 site📍 Mayfield Heights Novartis Pharmaceuticals · Tests: LOU064, Placebo Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa NCT06058520EARLY Phase 11 site📍 Minneapolis University of Minnesota · Tests: Fecal Microbiota - lyophilized, Placebo drug
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy